Gastroenteropancreatic Neuroendocrine Tumors
📧 Sign up to get email alerts when something new happens for Gastroenteropancreatic Neuroendocrine Tumors.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors [Phase 2, Phase 3]
A Phase 2/3 clinical trial is evaluating sirolimus for injection (albumin-bound) in combination with octreotide long-acting injection in pat…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors [NA]
Clinical trial update for a dual tracer PET imaging study using 68Ga-DOTATATE and 18F-FDG in grade 2 and grade 3 gastroenteropancreatic neur…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs
Italian prospective observational study evaluating the effectiveness and outcomes of Lutathera treatment in patients with gastroenteropancre…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: DCEUS to Assess Treatment Response to PRRT in GEP-NET [NA]
This trial update discusses using dynamic contrast-enhanced ultrasound (DCEUS) to assess response to peptide receptor radionuclide therapy (…
-
CLINICAL_TRIALS research · 2025-09-10Clinical Trial Update: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE [Phase 3]
Phase 3 clinical trial comparing Lutetium-177Lu-Edotreotide to best standard of care in well-differentiated aggressive grade-2/grade-3 gastr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-01-28Clinical Trial Update: Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs
A completed Asian trial evaluating Lanreotide Autogel for Gastroenteropancreatic neuroendocrine tumors. The snippet notes completion but doe…
-
CLINICAL_TRIALS trial_result · 2025-01-24Clinical Trial Update: Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients [Phase 4]
This document reports the results of a Phase 4 post-authorization safety study of LysaKare in adults with Gastroenteropancreatic neuroendocr…
-
CLINICAL_TRIALS withdrawal · 2024-04-29Clinical Trial Update: A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors [Phase 1, Phase 2]
This clinical trial update notes that the Phase 1/2 study evaluating the safety of combining Lutathera and Azedra for midgut gastroenteropan…
-
FDA approval · 2023-02-21FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application to Heritage Pharmaceuticals (Avet) for octreotide acetate, a generic product, under an ANDA.
-
CLINICAL_TRIALS trial_result · 2022-12-06Clinical Trial Update: TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors [Phase 2]
Phase 2 trial update for TEMCAP in grade 3 and low Ki-67 gastroenteropancreatic neuroendocrine tumors has completed.
-
CLINICAL_TRIALS trial_result · 2022-11-10Clinical Trial Update: 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs [Phase 3]
Phase 3 trial evaluating Lutetium-177 dotatate treatment prediction using multimodality imaging in refractory gastroenteropancreatic neuroen…
-
CLINICAL_TRIALS trial_result · 2022-10-14Clinical Trial Update: [68 Ga]-DOTANOC PET/CT in GEP-NETs [Phase 2, Phase 3]
A Phase 2/Phase 3 trial evaluating [68 Ga]-DOTANOC PET/CT imaging in gastroenteropancreatic neuroendocrine tumors has completed.
-
CLINICAL_TRIALS trial_result · 2022-09-28Clinical Trial Update: Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors [Phase 1, Phase 2]
Phase 1/2 trial evaluating pembrolizumab in combination with lanreotide depot for gastroenteropancreatic neuroendocrine tumors has completed…
-
FDA approval · 2022-02-09FDA Approved: OCTREOSCAN — Supplemental Application (Curium US LLC)
FDA documents a supplemental approval application for OCTREOSCAN (Indium-111 pentetreotide) submitted by Curium US LLC.
-
FDA approval · 2020-05-28FDA Approved: LUTATHERA — Supplemental Application (Advanced Accelerator Applications USA, Inc)
FDA approved a supplemental application for Lutathera (lutetium-177 dotatate) submitted by Advanced Accelerator Applications USA, Inc.
-
CLINICAL_TRIALS trial_result · 2020-02-07Clinical Trial Update: Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients [Phase 2]
Phase 2 trial update evaluating efficacy and safety of 177Lu-Dotatate PRRT in metastatic gastroenteropancreatic neuroendocrine tumors.
-
CLINICAL_TRIALS trial_result · 2019-10-02Clinical Trial Update: 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET [Phase 1, Phase 2]
Clinical trial update for 68Ga-OPS202 imaging agent in gastroenteropancreatic neuroendocrine tumors; study completed with results posted.
-
FDA approval · 2018-02-22FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
The FDA approved a supplemental application for Somatuline Depot (lanreotide acetate) submitted by Ipsen Biopharmaceuticals, Inc.
-
FDA approval · 2017-07-10FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Sagent Pharmaceuticals)
FDA approves a supplemental application for Octreotide Acetate submitted by Sagent Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2016-09-07Clinical Trial Update: Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors [Phase 1, Phase 2]
A terminated Phase 1/2 study evaluated the diagnostic accuracy of Gallium-68-DOTATATE PET/CT compared with Indium-111-pentetreotide SPECT/CT…
-
FDA approval · 2014-12-16FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
The FDA approved a supplemental application for Somatuline Depot (lanreotide acetate) from Ipsen Biopharmaceuticals, Inc., updating regulato…
-
FDA approval · 2014-10-28FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
The FDA approved a supplemental application for Somatuline Depot (lanreotide acetate) from Ipsen Biopharmaceuticals, Inc., expanding its app…
-
FDA approval · 2014-01-30FDA Approved: SANDOSTATIN LAR DEPOT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Sandostatin LAR Depot (octreotide acetate) submitted by Novartis Pharmaceuticals Corporation. Th…
-
FDA approval · 2011-03-04FDA Approved: SOMATULINE DEPOT — Supplemental Application (Ipsen Biopharmaceuticals, Inc.)
FDA approved a supplemental application for Somatuline Depot (lanreotide acetate) submitted by Ipsen Biopharmaceuticals, Inc.
-
FDA approval · 2007-08-30FDA Approved: SOMATULINE DEPOT — Original Application (Ipsen Biopharmaceuticals, Inc.)
The FDA approved Somatuline Depot (lanreotide acetate) under the Original Application for Ipsen Biopharmaceuticals.